2. Search Result
Search Result
Pathways Recommended: PROTAC
Results for "

PROTAC negative Control

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161157
    dTAG-13-NEG

    		PROTACs Cancer
    dTAG-13-NEG is a negative control of dTAG-13 (HY-114421). dTAG-13, a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 F36V with expression of FKBP12F36V in-frame with a protein of interest .
    dTAG-13-NEG
  • HY-W047688
    tert-Butyl (10-aminodecyl)carbamate

    1-Boc-1,10-diaminodecane

    		 PROTAC Linkers Cancer
    tert-Butyl (10-aminodecyl) carbamate (1-Boc-1,10-diaminodecane) is a synthetic intermediate that serves as a PROTAC linker in PROTAC synthesis and other conjugation applications. tert-Butyl (10-aminodecyl) carbamate is an alkane chain with a terminal amine and a Boc-protected amino group. The amine group can react with carboxylic acids, active NHS esters, carbonyl groups (ketones, aldehydes), etc. The Boc group can be deprotected under mild acidic conditions to form a free amine .
    tert-Butyl (10-aminodecyl)carbamate
  • HY-161828A
    (S)-JWZ-5-13

    		PROTACs CDK Cancer
    (S)-JWZ-5-13 (compound 17-Neg), a PROTAC CDK7 degrader, is a negative control compound of JWZ-5-13 (HY-161828). (S)-JWZ-5-13 displays similar in vitro CDK7 inhibition (IC50 = 21.1 nM) to JWZ-5-13, but fails to induce CDK7 degradation in cells .
    (S)-JWZ-5-13
  • HY-157579
    MS154N

    		PROTACs EGFR Cancer
    MS154N (compound 28) is the negative control of MS39 (HY-157581). MS154N is composed of PROTAC target protein ligand EGFR ligand-11 (HY-168305) (red part), E3 ligase ligand 4-Hydroxy-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (HY-W441376) (blue part) and PROTAC Linker 8-Iodooctan-1-amine (HY-168306) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Me-Thalidomide-O-C8-NH2 (HY-168307) .
    MS154N
  • HY-107425B
    cis-MZ 1 hydrate

    		Epigenetic Reader Domain Cancer
    cis-MZ 1 hydrate is a negative control for BRD4-targeted PROTAC MZ 1 (HY-107425). cis-MZ 1 or MZ 1 is a combination of the von Hippel-Lindau ligand (red part in the structural formula) and the BRD4 ligand (blue part in the structural formula). The Kd of MZ 1 for BRD4 BD1/2 was 382 nM and 120 nM, respectively .
    cis-MZ 1 hydrate
  • HY-W586822
    N-Methylated pomalidomide

    Pomalidomide-methyl

    		 Ligands for E3 Ligase Cancer
    N-methylated pomalidomide (Pomalidomide-methyl), a derivative of Pomalidomide (HY-10984), is a cereblon (CRBN) ligand. N-methylated pomalidomide is unable to recruit CRBN that can be used as a negative control for Pomalidomide. N-methylated pomalidomide can be used to synthesize PROTAC .
    N-Methylated pomalidomide
  • HY-136257
    CMP98

    		PROTACs Others
    CMP98, a PROTAC, is unable to induce degradation of VHL. CMP98 can be used as a negative control compound for CM11 . CMP98 consists of two von Hippel-Lindau ligands on their active domain.
    CMP98
  • HY-170859A
    AH081

    		PROTACs Casein Kinase Cancer
    AH081 (Compound 38) is a CK1δ/ε PROTAC degrader. AH081 is the negative control compound of AH078 (HY-170859). AH081 has inhibitory but no degradation activity for CK1δ/ε by using an inactive stereoisomer of the VHL ligand . Pink: CK1δ/ε ligand (HY-148251); Blue: VHL ligase ligand (HY-125845B); Black: linker
    AH081
  • HY-159016
    SIAIS630121-NC

    		PROTACs Cancer
    SIAIS630121-NC (compound 630121-NC) is a negative control for NAMPT (nicotinamide phosphoribosyltransferase) PROTAC degrader SIAIS630121. SIAIS630121-NC shows no NAMPT degradation capability at all .
    SIAIS630121-NC
  • HY-161157A
    dTAG-13-NEG TFA

    		PROTACs Cancer
    dTAG-13-NEG TFA is a negative control of dTAG-13 (HY-114421). dTAG-13, a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 F36V with expression of FKBP12F36V in-frame with a protein of interest .
    dTAG-13-NEG TFA
  • HY-162816
    PROTAC HPK1 Degrader-3

    		PROTACs MAP4K Cancer
    PROTAC HPK1 Degrader-3 (compound C3) is an orally effective PROTAC targeting HPK1 (DC50=21.26 nM). HPK1 is a negative regulator of T cell receptors, which can lead to T cell dysfunction after abnormal activation. PROTAC HPK1 Degrader-3 can inhibit SLP76 and NF-κB signaling pathways and inhibit MAPK signal transduction, and has anticancer activity and immune activation. PROTAC HPK1 Degrader-3 has a certain oral bioavailability and can be combined with PD-L1 antibody therapy to achieve a tumor growth inhibition rate of 65.58%. PROTAC HPK1 Degrader-3 is composed of E3 ligase ligand Thalidomide (HY-14658; blue part), PROTAC linker tert-Butyl 3-oxoazetidine-1-carboxylate (HY-40146; black part), and target protein ligand HPK1-IN-51 (HY-162842; red part); the activity control of the target protein ligand can be HPK1 ligand 1 (HY-162841) [1] .
    PROTAC HPK1 Degrader-3
  • HY-W1005059
    N-Methylthalidomide

    		Ligands for E3 Ligase Cancer
    N-Methylthalidomide is a cereblon ligand derivative that acts as an E3 ubiquitin ligase ligand for the synthesis of PROTAC LLC0424N (HY-185557). LLC0424N serves as a negative control for NSD2 PROTAC degrader LLC0424 (HY-161574), with weak ability to induce NSD2 degradation and low growth inhibitory effect on cancer cells carrying NSD2 mutations .
    N-Methylthalidomide
  • HY-160423
    MS8815N

    		PROTACs Histone Methyltransferase Cancer
    MS8815N is a negative control of EZH2 PROTAC degrader MS8815 (HY-148334). MS8815N is incapable of recruiting the VHL E3 ligase but retains the same EZH2 binding moiety and linker. MS8815N can be used for triple-negative breast cancer (TNBC) research .
    MS8815N
  • HY-183100
    UNC8461

    		PROTACs IKK Apoptosis Cancer
    UNC8461 is a PROTAC and is negative control CRBN-recruiting PROTAC analog of UNC8209 (HY-183098). UNC8461 features a methyl group substitution on its CRBN ligand to disrupt CRBN binding. UNC8461 fails to reduce TBK1, AAK1, GAK, and AURKA protein levels in renal cancer cells. UNC8461 does not suppress 3-D soft agar colony formation in renal cancer cells, and exerts modest, partial inhibition on colony formation in some renal cancer cells .
    UNC8461
  • HY-180329
    CG 858-Neg

    		Ligands for E3 Ligase ERK Raf
    CG 858-Neg (compound 13) is a negative control for Thalidomide (HY-14658)-derived PROTAC degraders, targeting BRAF and BRAF V600E with Ki values ​​of 9.5 nM and 14.4 nM, respectively. CG 858-Neg inhibits downstream ERK phosphorylation and suppresses BRAF V600E-driven melanoma (e.g., A375 cells, IC50=492 nM) and colorectal cancer (e.g., HT-29 cells, IC50=459 nM) cells. CG 858-Neg can be used in research related to melanoma and colorectal cancer .
    CG 858-Neg

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: